4//SEC Filing
PEREGRINE PHARMACEUTICALS INC 4
Accession 0001019687-13-003917
CIK 0000704562operating
Filed
Oct 16, 8:00 PM ET
Accepted
Oct 17, 8:28 PM ET
Size
11.1 KB
Accession
0001019687-13-003917
Insider Transaction Report
Form 4
KING STEVEN W
DirectorPresident & CEO
Transactions
- Award
Stock Option (right to buy)
2013-10-15+250,000→ 1,933,500 totalExercise: $1.39Exp: 2023-10-15→ Common Stock (250,000 underlying) - Award
Common Stock, $.001 par value
2013-10-15+100,000→ 187,403 total - Disposition to Issuer
Stock Option (right to buy)
2013-10-15−250,000→ 1,683,500 totalExercise: $0.46Exp: 2022-05-04→ Common Stock (250,000 underlying)
Footnotes (5)
- [F1]On October 15, 2013, pursuant to a written mutual agreement between the issuer and the reporting person, the issuer canceled an option for 250,000 shares of common stock granted to the reporting person on May 4, 2012. In partial consideration for the cancellation of the option, the reporting person received 100,000 shares of common stock.
- [F2]Represents the portion of a stock option grant that was originally granted to the reporting person on May 4, 2012 and was surrendered and cancelled pursuant to the terms of an agreement, dated October 15, 2013, by and between the reporting person and the issuer. Pursuant to the agreement and in consideration for the surrender and cancellation of the stock option grant, the reporting person received (1) 100,000 shares of common stock ("Stock Award"), (2) an option to purchase 250,000 shares of common stock, having an exercise price of $1.39 per share and (3) $83,685 in cash to cover applicable statutory state and federal income and employment taxes based on the statutory withholding rates resulting from the Stock Award.
- [F3]On October 15, 2013, pursuant to a written mutual agreement between the issuer and the reporting person, the issuer canceled an option for 250,000 shares of common stock granted to the reporting person on May 4, 2012. In partial consideration for the cancellation of the option, the reporting person received a replacement option for 250,000 shares, having an exercise price of $1.39 a share.
- [F4]The cancelled option provided for vesting in eight (8) equal quarterly installments over a two (2) year period beginning August 4, 2012 and each quarter thereafter until fully-vested.
- [F5]The vesting terms of the new option grant are identical to the vesting schedule of the cancelled option grant, whereby, 156,250 options vest immediately as the reporting person received credit for the time elapsed since the original option grant, and the remaining 93,750 unvested options shall vest in three (3) equal quarterly installments beginning November 4, 2013 and each quarter thereafter until fully-vested.
Documents
Issuer
PEREGRINE PHARMACEUTICALS INC
CIK 0000704562
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000704562
Filing Metadata
- Form type
- 4
- Filed
- Oct 16, 8:00 PM ET
- Accepted
- Oct 17, 8:28 PM ET
- Size
- 11.1 KB